Ian Quirt

18.8k total citations
80 papers, 2.8k citations indexed

About

Ian Quirt is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ian Quirt has authored 80 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 23 papers in Molecular Biology and 20 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ian Quirt's work include Melanoma and MAPK Pathways (17 papers), Cutaneous Melanoma Detection and Management (15 papers) and Sarcoma Diagnosis and Treatment (13 papers). Ian Quirt is often cited by papers focused on Melanoma and MAPK Pathways (17 papers), Cutaneous Melanoma Detection and Management (15 papers) and Sarcoma Diagnosis and Treatment (13 papers). Ian Quirt collaborates with scholars based in Canada, United States and New Zealand. Ian Quirt's co-authors include B. Cummings, Victor Fornasier, Manya Charette, Kate Bak, Brian O’Sullivan, Shailendra Verma, Teresa M. Petrella, Robert S. Bell, Charles Catton and Susan Burdette-Radoux and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Ian Quirt

80 papers receiving 2.7k citations

Peers

Countries citing papers authored by Ian Quirt

Since Specialization

Citations

This map shows the geographic impact of Ian Quirt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian Quirt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian Quirt more than expected).

Fields of papers citing papers by Ian Quirt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ian Quirt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian Quirt. The network helps show where Ian Quirt may publish in the future.

Co-authorship network of co-authors of Ian Quirt

This figure shows the co-authorship network connecting the top 25 collaborators of Ian Quirt. A scholar is included among the top collaborators of Ian Quirt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ian Quirt. Ian Quirt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma 2016 ·Investigational New Drugs ·Elaine McWhirter, Ian Quirt, Thomas F. Gajewski, Gregory R. Pond, Lisa Wang, (unknown), Amit M. Oza	7
2	Phase II trial of vorinostat in advanced melanoma 2014 ·Investigational New Drugs ·Naomi B. Haas, Ian Quirt, Sébastien J. Hotte, Elaine McWhirter, (unknown), Samuel Litwin, Peter D. Adams, Tony McBryan, (unknown), Lainie P. Martin, (unknown), R. Katherine Alpaugh, James Zweibel, Amit M. Oza	47
3	Melanoma Early Detection and Awareness 2014 ·American Journal of Therapeutics ·Alberto Julius Alves Wainstein, Salvador Martín‐Algarra, Lars Bastholt, Gabriela Cinat, Lev Demidov, Jean‐Jacques Grob, Jun Guo, Peter Hersey, Enrique Espinosa, Jacob Schachter, (unknown), Ian Quirt, Axel Hauschild, Piotr Rutkowski	11
4	Adjuvant Interferon Therapy for Patients at High Risk for Recurrent Melanoma: An Updated Systematic Review and Practice Guideline 2012 ·Clinical Oncology ·Teresa M. Petrella, S. Verma, Karen Spithoff, Ian Quirt, David R. McCready	41
5	Small molecules and targeted therapies in distant metastatic disease 2009 ·Annals of Oncology ·Peter Hersey, Lars Bastholt, Vanna Chiarion‐Sileni, Gabriela Cinat, Reinhard Dummer, Alexander M.M. Eggermont, Enrique Espinosa, Axel Hauschild, Ian Quirt, Caroline Robert, Dirk Schadendorf	72
6	Intravenous iron and recombinant erythropoietin for the treatment of postoperative anemia 2006 ·Canadian Journal of Anesthesia/Journal canadien d anesthésie ·Keyvan Karkouti, Stuart A. McCluskey, Mohammed Ghannam, (unknown), Ian Quirt, Terrence M. Yau	68
7	CCI‐779 in metastatic melanoma 2005 ·Cancer ·Kim Margolin, Jeff Longmate, (unknown), Timothy W. Synold, Scott Christensen, Jeffrey S. Weber, Thomas F. Gajewski, Ian Quirt, James H. Doroshow	188
8	Epoetin Alfa in Cancer Patients 2001 ·Journal of Pain and Symptom Management ·Robert C. Turner, (unknown), Ronald L. Burkes, Félix Couture, William K. Evans, Glenwood Goss, Robert Grimshaw, Barbara Melosky, Alexander Paterson, Ian Quirt	34
9	Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial 1999 ·Gene Therapy ·A. Keith Stewart, Norman J. Lassam, Ian Quirt, Denis Bailey, Lorne Rotstein, Mel Krajden, Sophie Dessureault, Steven Gallinger, (unknown), Yong Wan, Christina Addison, R C Moen, Jack Gauldie, Felicia L. Graham	108
10	Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. 1997 ·Journal of Clinical Oncology ·Joseph M. Connors, Paul Klimo, Grenfell Adams, B F Burns, Ian Cooper, Ralph M. Meyer, Sean OʼReilly, Joe Pater, Ian Quirt, Anna Sadura, Chaim Shustik, Jamey Skillings, Simon Sutcliffe, Savita Verma, (unknown), Benny Zee	113
11	Cost-Benefit Analysis of Prophylactic Granulocyte Colony-Stimulating Factor During CHOP Antineoplastic Therapy for Non-Hodgkinʼs Lymphoma 1997 ·PharmacoEconomics ·George Dranitsaris, (unknown), Ian Quirt	12
12	Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. 1996 ·Journal of Clinical Oncology ·James J. Rusthoven, Ian Quirt, N. Iscoe, P. B. McCulloch, (unknown), Reinhard Lohmann, Jens‐Ulrik Stæhr Jensen, Susan Burdette-Radoux, A. Bodurtha, H. Silver, S. Verma, George Armitage, Benny Zee, Kathleen Bennett	118
13	Phase II trial of 10-EDAM in advanced soft tissue sarcoma 1994 ·Annals of Oncology ·Margaret A. Knowling, V. Bramwell, E. Eisenhauer, (unknown), A. Bodurtha, Ian Quirt	7
14	A phase II study of weekly Edatrexate (10-EDAM) in metastatic melanoma 1993 ·Annals of Oncology ·Sunil Verma, Ian Quirt, E. Eisenhauer, N. Iscoe, (unknown), A. Bodurtha, J. A. Davidson	7
15	Escalated as Compared with Standard Doses of Doxorubicin in BACOP Therapy for Patients with Non-Hodgkin's Lymphoma 1993 ·New England Journal of Medicine ·Ralph M. Meyer, Ian Quirt, Jamey Skillings, M. Christine Cripps, Vivien Bramwell, Brian Weinerman, Mary Gospodarowicz, Bruce F. Burns, (unknown), Lois E. Shepherd, Benny Zee, William M. Hryniuk	45
16	Outcome and prognostic factors in soft tissue sarcoma in the adult 1993 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), Brian O’Sullivan, Charles Catton, Robert S. Bell, Victor Fornasier, B. Cummings, Desirée Hao, (unknown), Ian Quirt	156
17	Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group. 1991 ·Journal of Clinical Oncology ·Ian Quirt, W Shelley, Joe Pater, A. Bodurtha, (unknown), T. A. McPherson, Alexander Paterson, Ross L. Prentice, H. Silver, Andrew R. Willan	58
18	Lecture handouts of projected slides in a medical course 1990 ·Medical Teacher ·Dominick Amato, Ian Quirt	5
19	Toxicity of oral N-methylformamide in three phase II trials: a report from the National Cancer Institute of Canada Clinical Trials Group. 1986 ·PubMed ·(unknown), (unknown), I B Kerr, Ian Quirt	10
20	Leukemia on myeloma. 1972 ·BMJ ·Ian Quirt, (unknown), (unknown)	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact